Tandem Diabetes Care, Inc. (TNDM) Stock Analysis & Investment Frameworks

Tandem Diabetes Care, Inc. (TNDM) stock analysis on Invetso. Review Tandem Diabetes Care, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.

Tandem Diabetes Care, Inc. Company Overview

Tandem Diabetes Care, Inc. Key Financial Metrics

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.

Tandem Diabetes Care, Inc. Investment Frameworks

Invetso analyzes Tandem Diabetes Care, Inc. (TNDM) across the following frameworks:

Explore More TNDM Research